Rearming the immune system with personalized allogeneic CAR-T cell therapy

Off-the-shelf cellular immunotherapies have historically been expensive to produce and carry safety risks such as graft-versus-host disease (GvHD). David McCall, Senior Editor at BioInsights, speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about overcoming these and other barriers through the combination of allogeneic cell therapy and personalized medicine.

Please enter your email to access content Read now